Sagimet Biosciences (STU:0O2) Change In Payables And Accrued Expense: €-1.72 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0O2 Sagimet Biosciences Inc STU:0O2
18 GF Score
Price €9.08
! 4 Warning Signs
View Full Analysis

What is Sagimet Biosciences Change In Payables And Accrued Expense?

Sagimet Biosciences STU:0O2 +1.11% 18 Change In Payables And Accrued Expense is €-1.72 Mil as of Jun. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 18/100. The stock has 4 warning signs investors should review.

Sagimet Biosciences's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2026 was €-0.21 Mil. It means Sagimet Biosciences's Accounts Payable & Accrued Expense declined by €0.21 Mil from Mar. 2026 to Jun. 2026 .

Sagimet Biosciences's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2025 was €0.79 Mil. It means Sagimet Biosciences's Accounts Payable & Accrued Expense increased by €0.79 Mil from Dec. 2024 to Dec. 2025 .

Sagimet Biosciences Change In Payables And Accrued Expense Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences Change In Payables And Accrued Expense Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Payables And Accrued Expense
Get a 7-Day Free Trial 0.50 2.75 0.11 -0.87 0.79

Sagimet Biosciences Quarterly Data
Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 1.33 -3.39 0.55 -0.21
STU:0O2
18GF Score
Sagimet Biosciences Inc STU:0O2
Change In Payables And Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Change In Payables And Accrued Expense of €-1.72 Mil mean?
Sagimet Biosciences (STU:0O2) has a Change In Payables And Accrued Expense of €-1.72 Mil as of Jun. 2026. Change In Payables And Accrued Expense is any increase or decrease between periods of the payables and accrued expense. View historical data on Sagimet Biosciences and its competitors.
Is Sagimet Biosciences' Change In Payables And Accrued Expense too high?
Sagimet Biosciences' current Change In Payables And Accrued Expense is €-1.72 Mil. Overall, Sagimet Biosciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Change In Payables And Accrued Expense compare to CABA and OVID?
Sagimet Biosciences' Change In Payables And Accrued Expense of €-1.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Payables And Accrued Expense for a Biotechnology company?
A good Change In Payables And Accrued Expense depends on the Biotechnology industry context. However, Change In Payables And Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Payables And Accrued Expense mean?
A high Change In Payables And Accrued Expense can signal that a stock is expensive relative to its fundamentals. Change In Payables And Accrued Expense is any increase or decrease between periods of the payables and accrued expense. View historical data on Sagimet Biosciences and its competitors. Sagimet Biosciences's current Change In Payables And Accrued Expense is €-1.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Change In Payables And Accrued Expense of €-1.72 Mil. The current Change In Payables And Accrued Expense is €-1.72 Mil. Sagimet Biosciences' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Payables And Accrued Expense calculated?
Change In Payables And Accrued Expense is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Change In Payables And Accrued Expense is €-1.72 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
18GF Score

Get the complete analysis for STU:0O2

Change In Payables And Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.08
Price